Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cannabidiol - GW Pharmaceuticals

Drug Profile

Cannabidiol - GW Pharmaceuticals

Alternative Names: CBD - GW Pharmaceuticals; Epidiolex; Epidyolex; GW-42003; GWP-42003; GWP-42003-P

Latest Information Update: 13 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GW Pharmaceuticals
  • Developer GW Pharmaceuticals; University of Alabama at Birmingham; University of Utah
  • Class Analgesics; Anti-inflammatories; Anti-ischaemics; Antiacnes; Antiepileptic drugs; Antihyperglycaemics; Antihyperlipidaemics; Antineoplastics; Antipsoriatics; Antipsychotics; Antirheumatics; Anxiolytics; Cannabinoids; Cyclohexenes; Drug withdrawal therapies; Heart failure therapies; Hepatoprotectants; Muscle relaxants; Neuroprotectants; Obesity therapies; Skin disorder therapies; Small molecules
  • Mechanism of Action Antioxidants; Cannabinoid receptor CB1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lennox-Gastaut syndrome; Dravet syndrome; Cerebral ischaemia; Infantile spasms; Tuberous sclerosis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Dravet syndrome; Lennox-Gastaut syndrome
  • Phase III Infantile spasms; Rett syndrome; Tuberous sclerosis
  • Phase II Epilepsy; Opioid abuse; Parkinson's disease; Schizophrenia
  • Phase I Cerebral ischaemia
  • Preclinical Duchenne muscular dystrophy; Ovarian cancer
  • Discontinued Dyslipidaemias; Non-alcoholic fatty liver disease; Type 2 diabetes mellitus; Ulcerative colitis

Most Recent Events

  • 11 Nov 2019 The National Institute for Health and Care Excellence (NICE) recommend cannabidiol oral solution used with clobazam for treatment of Dravet and Lennox-Gastaut syndromes
  • 10 Nov 2019 GW Pharmaceuticals intends to launch cannabidiol in Lennox-Gastaut syndrome and Dravet syndrome in Germany, Spain, France, Italy and United Kingdom in 2019
  • 05 Nov 2019 GW Pharmaceuticals announces intention to submit MAA to EMA for Tuberous sclerosis in the first quarter of 2020
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top